Optimum Bio Innovations Limited (OBIL) has developed a proprietary platform technology – a group of technologies used as a base upon which other applications, processes or technologies are developed.
The core technology, which is protected by trade secret, came about by way of accidental discovery while pursing environmental science related opportunities in 2012 – specifically in emission reduction. The theory was that the technology was making oxygen more bio-available.
In 2014 the first medical application of the current Optimum Bio technology was born out of the Founder’s desperation to help his father manage debilitating symptoms from a range of life threatening illnesses. Measurable results were observed in improved pain management, circulation, wound recovery and mental acuity.
As a result, over the next three years (2014 – 2017) of experimental research & development, 100+ people were directly referred across a range of differing illnesses seeking symptom relief in one or more of the same areas.
Optimum Bio Innovations Limited was formally established in May 2017. The Company’s focus is solely on Research and Development (R&D) – to develop application specific Proof Of Concepts (POCs) in New Zealand that, once validated, will be spun out into separate, wholly-owned subsidiaries.
By 2022, over 40,000 hours have gone in to R&D – to determine how the technology can be adapted and applied to enhance many living organisms.
Optimum Bio Sound Therapy (OBST) is the first application to be pursued commercially – as a globally scalable SaaS offering in the telehealth space.
OBST is an FDA Class I Medical Device used to help people ease the impact of pain resulting from multiple conditions, which can lead to a reduction in one’s overall quality of life. Drug free, pain free and non-invasive, OBST is streamed directly to you in the comfort, convenience and privacy of your own home as a telehealth therapy.